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INTRODUCTION
Endothelial progenitor cells (EPCs)
have been shown to promote revascular-
ization of ischemic tissues (1) and tumors
(2). These cells, therefore, have the poten-
tial to be harnessed for cell-based thera-
pies to induce vascular repair. Recent
clinical trials have demonstrated that
EPC delivery to ischemic tissue is feasi-
ble, safe and effective for the treatment
of myocardial infarction (3) and periph-
eral arterial disease (4). EPCs have also
been described as critical regulators of
the angiogenic switch in metastatic pro-
gression (5), and there have been re-
ported attempts to control tumor growth
by targeting EPCs, either by using EPCs
as vectors for gene delivery to tumors (6)
or by blocking the recruitment of mobi-
lized EPCs after chemotherapy (7).
Despite an exponential increase in EPC
research, controversy still surrounds the
definition of EPCs (8), and cell-
therapy–based clinical studies in particu-
lar have often used ill-defined, heteroge-
neous cells. Currently, EPCs are regarded
as blood circulating cells that contribute
to angiogenesis, although the scope of
this definition is extremely broad and in-
cludes a diverse range of cell types
(9,10). Recently we have characterized
two EPC subtypes in vitro: early EPCs
(herein called myeloid angiogenic cells
[MACs]) and outgrowth endothelial cells
(OECs) (11) (also known as endothelial
colony-forming cells). OECs possess
well-defined endothelial progenitor char-
acteristics such as commitment to an en-
dothelial lineage, de novo tubulogenic po-
tential and an ability to fully incorporate
into a resident vascular network (12). In
contrast, MACs show none of these EPC
properties; however, MACs may still
play a significant role in therapeutic an-
giogenesis (13,14). The proangiogenic,
cytokine-mediated effects of various EPC
subtypes have been described (15–20).
However, the current study is the first in-
vestigation of the underlying molecular
mechanisms whereby an important EPC
subtype (MACs) can promote angiogene-
sis downstream of cytokine release. In
particular, our data demonstrate that
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vates VEGFR2 and induces phosphorylation of extracellular signal-regulated kinases. Further transcriptomic and immunopheno-
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MAC-derived interleukin-8 (IL-8) is
 capable of transactivating vascular
 endothelial growth factor receptor 2
(VEGFR2) independently of extracellular
VEGF.
EPCs are not the only cell population
that influences angiogenesis; mounting
evidence indicates that myeloid cells also
regulate this process (21). Distinct
myeloid cell populations, such as tumor-
associated macrophages (22,23), Tie2-
 expressing monocytes (24) and myeloid-
derived suppressor cells (25), have been
implicated as key players in the angio-
genic process. Although initially these
monocytic subpopulations were de-
scribed as having distinct phenotypes, it
is now evident that they exhibit some
overlapping markers (26) and share simi-
lar proangiogenic properties. In fact, they
have been associated with alternative M2
macrophages, which are characterized as
being antiinflammatory, proangiogenic
cells involved in tissue repair and vascu-
lar remodeling (27). Because MACs have
been previously shown to have mono-
cytic features, in the current study we
addressed the important question of
whether these cells could, in fact, be
linked to alternative M2 macrophages. It
is crucial to assess MACs in relation to
the M1/M2 polarization phenotypes be-
cause the macrophage contribution to
angiogenesis is radically dictated by their
polarization state. Such information has
major therapeutic value because various
hematopoietic/myeloid cells, including
MACs, are already being used in the
clinical setting.
MATERIALS AND METHODS
Cell Isolation and Culture
Circulating proangiogenic cells (here-
after referred to as MACs) were isolated
from human peripheral blood according
to previously established protocols (11).
Fresh human peripheral blood (40 mL)
was obtained with full ethics approval
from healthy volunteers aged 25–35
years who were nonsmokers and were
not receiving any medication. Briefly,
mononuclear cells were obtained by den-
sity gradient centrifugation and resus-
pended in EGM-2-MV medium (Lonza,
Slough, UK) supplemented with 10%
fetal bovine serum (FBS) and plated on
flasks coated with  fibronectin (Sigma,
Gillingham, UK) at a density of 2 × 106
cells/mL. MACs at days 7–9 were used
for experiments.
Primary retinal capillary-derived mi-
crovascular endothelial cells (RMECs)
were freshly prepared from bovine eyes
according to standard isolation proce-
dures previously described (28). RMECs
were cultured on 1% gelatin-coated
flasks, with DMEM (PAA Labs GmbH,
Pasching, Austria) supplemented with
10% porcine serum (Sigma), 100 μg/mL
insulin (Sigma), 1 mg/mL heparin
(Sigma), and 500 mg/mL Primocin
(Auto gen Bioclear, Wiltshire, UK).
RMECs at passages 3 to 6 were used for
experiments.
The human microvascular endothelial
cell line (HMEC-1) was provided by the
Centers for Disease Control and Preven-
tion, Emory University School of Medi-
cine, Atlanta, Georgia. HMEC-1 were
grown in MCDB-131 medium (Invitro-
gen, Paisley, UK) supplemented with
10% FBS, 10 ng/mL epidermal growth
factor (BD Biosciences Europe, Erembod -
egem, Belgium), 1 μg/mL hydrocortisone
(Sigma) and 10 mmol/L L-glutamine
(Sigma).
In Vitro Tubulogenesis Assay
RMECs and MACs were labeled with
a PKH membrane-labeling kit (Sigma)
prior to experiments. RMECs were
mixed in a 4:1 ratio with MACs and sus-
pended in growth factor reduced
 Matrigel (BD Biosciences), then 50-μL
aliquots were spotted onto a 24-well
plate. After polymerization, spots were
covered with DMEM containing 5%
porcine serum and respective treatments.
After 72 h, wells were assessed for the
presence of tubules, defined as an inter-
connected vascular network of elongated
tubelike structures. In a separate set of
experiments, conditioned medium ob-
tained from MACs was used in this
tubulogenesis model. To gain insight into
the molecular mechanisms underlying
the effect of MACs on RMECs, we neu-
tralized IL-8 and VEGF by using
10 μg/mL of antihuman CXCL8/IL-8
(R&D Systems, Abingdon, UK) and
1 μg/mL of antihuman VEGF (R&D Sys-
tems). Respective IgG isotype controls
were also used. Images were acquired by
using a laser confocal microscope
(Nikon, Tokyo, Japan), and vascular tube
area and length were quantified by using
Volocity (PerkinElmer, Waltham, MA,
USA) and NIS elements (Nikon) soft-
ware, respectively. All measurements
were done on bidimensional images.
Flow Cytometry
We prepared 1 × 106 cells for staining
by filtering through 35-μm nylon mesh
(BD Biosciences, Bedford, UK) and resus-
pended them in 100 μL of flow cytome-
try staining buffer (eBioscience, San
Diego, CA, USA). Cells were incubated
with fluorophore-conjugated antibodies
against CD45, CD14, CD68, CD163,
CD83, CD209, CD16 (eBioscience),
CD206 (BD Biosciences) and Tie2 (Bio -
Legend, San Diego, CA, USA) for 45 min
at 4°C. For CD68 staining, cell fixation
and permeabilization were required be-
cause CD68 is predominantly an intra -
cellular protein. After staining, cells were
washed and resuspended in 500 μL stain-
ing buffer for analysis performed by
using a FACSCalibur flow cytometer (BD
Biosciences) with CellQuest (BD Bio-
sciences) and FlowJo (Tree Star, Ashland,
OR, USA) software. At least 15,000
events were acquired per sample, and re-
spective immunoglobulin (Ig)G isotype
controls were used to determine accurate
settings for data analysis.
Human Angiogenesis Protein Array
Medium was obtained from coculture
experiments and analyzed by using the
Proteome Profiler human angiogenesis
array (R&D Systems) in accordance with
manufacturer guidelines. Briefly, samples
were adjusted to a final volume of
1.5 mL with array buffer and mixed with
a detection antibody cocktail for 1 h.
After a membrane-blocking step, sam-
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ples containing antibody cocktail were
then added to membranes and incubated
overnight at 4°C on a rocking platform.
Next, membranes were given several
washes and incubated with strepta-
vidin–horseradish peroxidase secondary
antibody (R&D Systems). Spots were de-
tected by using chemiluminescence (Mil-
lipore, Billerica, MA, USA) and densito-
metry was quantified by using LabWorks
software (PerkinElmer).
RNA Extraction and Microarray
Analysis
Total RNA was extracted by using an
RNAqueous kit (Ambion, Cambridge -
shire, UK), and 1 μg of RNA from each
cell sample was labeled and hybridized
to an Illumina WG-6 v3.0 Expression
Beadchip (Illumina, San Diego, CA,
USA). Samples analyzed in the array
were three biological replicates for pe-
ripheral blood (PB)-derived MACs and a
single sample of PB-derived CD14+
monocytes. Gene expression data ob-
tained from Illumina Beadstudio was
normalized by using an “R” bioconduc-
tor with a “lumi” package. Data were
processed and analyzed by using the
 National Institute on Aging (NIA) array
(Bethesda, MD, USA), GenePattern
(Broad Institute, Cambridge, MA, USA),
and integrative visual analysis tool for
biological networks and pathways
(visANT) software (Boston University,
Boston, MA, USA). Microarray data are
available at the NCBI Gene Expression
Omnibus (GEO) with accession number
GSE20283.
Real-Time Reverse-Transcription
Polymerase Chain Reaction
Total RNA was isolated from three dif-
ferent biological replicates for MACs and
CD14+ monocytes, respectively, by using
the RNAqueous kit (Ambion), including
the DNAse digestion step. Complemen-
tary DNA (cDNA) was synthesized from
500 ng of RNA by using randon hexam-
ers and Superscript II (Invitrogen).
Quantitative real-time polymerase chain
reaction (PCR) was performed with 2×
Maxima SYBR Green qPCR Mastermix
(Fermentas, York, UK) in 10-μL reactions
containing 2 μL of 1:15 cDNA dilution
and 0.5 μmol/L of gene-specific primers
for 45 cycles, including denaturation at
94°C for 10 s, annealing at 55°C for 15 s,
and extension at 72°C for 15 s in a 
LightCycler 480 (Roche, Welwyn Garden
City, UK). Pairs of primers used for 
amplification of target genes were:
CD163, AGGATGCTGGAGTGATTTGC
(forward) and CCAGCC GTC ATC ACA
TAT TG (reverse); CCL2, TCT GTG CCT G
CT GCT CAT AG (forward) and GTG AC
TGGG GCA TTG ATT G (reverse); MSR1,
GGGAACATTCTCAGACCTTG (for-
ward) and AAT CCT CGT GGA CCA CTT TC
(reverse); MMP-9, AGT GGC ACC A CC ACA
ACA TC (forward) and ACA CGC GAG T
GAAGGTGAG (reverse); IL-1β, CTGAT
GGCCCTAAACAGATG (forward) and
GTC GGA GAT TCG TAG CTG GAT (re-
verse); PTGS2, GGC TAG ACA GCG TAA
ACT GC (forward) and TAGATGCTCA
GGGACTTGAGG (reverse); TNFSF10,
TCA CAG TGC TCC TGC AGT CT (forward)
and TGG GGT CCC AAT AAC TGT CA (re-
verse); VEGFB, CTG TCT CCC AGC CTG
ATG (forward) and AGTCAAGGGC
ACCAC CAC (reverse); IL-10, GTCAT
CGATTTCTTCCCTGTG (forward) and
ACT CAT GGC TTT GTA GAT GCCT (re-
verse); RPL11 (housekeeping gene), 
TTC AGC ATC GCA GAC AAG AAGC (for-
ward) and TTT GCC AGG AAG GAT
GATCCCA (reverse). The relative gene
expression was determined by using
REST software (Qiagen, Dorking, Sur-
rey, UK).
Protein Extraction, Immunoprecipitation
and Western Blotting
Protein was extracted by lysing cells
in 1× RIPA buffer (Thermo Scientific,
Leicestershire, UK) containing protease
and phosphatase inhibitors with EDTA
(Thermo Scientific). Immunoprecipita-
tion was performed for VEGFR2 experi-
ments, and whole cell lysates were used
for extracellular signal-regulated kinase
(ERK) experiments. For immunoprecipi-
tation experiments, whole cell lysates
were diluted to 1 μg protein/μL of RIPA
buffer and first precleared by using pro-
tein A/G PLUS-agarose immunoprecipi-
tation beads (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Lysates were in-
cubated with rabbit monoclonal VEGF2
(Cell Signaling Technology, Danvers,
MA, USA) overnight at 4°C. Then, pro-
tein A/G PLUS-agarose immunoprecipi-
tation beads were added to lysates and
gently rocked for 4 h. After several
washing steps to eliminate nonspecific
binding, pellets were diluted in 2× LDS
sample buffer (Invitrogen) and heated at
95°C for 5 min to detach beads. After
electrophoresis, proteins were trans-
ferred to a polyvinylidene difluoride
(PVDF) membrane. Membranes were
blocked for 1 h in 3% Blotto, nonfat dry
milk (Santa Cruz Biotechnology) dis-
solved in Tris-buffered saline with 0.1%
Tween-20 (TBST). Total and phosphory-
lated FLK were detected with antibodies
from Santa Cruz Biotechnology, and
total and phosphorylated ERKs were de-
tected (antibodies from Cell Signaling).
After washing with TBST, respective
horse radish peroxidise–conjugated sec-
ondary antibodies (Santa Cruz Biotech-
nology) were applied, and blots were
developed by using a UVP bioimaging
system (Ultra-Violet Products Ltd,
 Cambridge, UK). PVDF membranes
were reprobed with a monoclonal anti-
body to β-actin (Cell Signaling) as a
loading control.
Phagocytosis Assay
To evaluate if MACs could carry out
phagocytosis, pHrodo™ Escherichia coli
BioParticles® (Invitrogen) were added to
the cell culture medium. After 2 h of in-
cubation at 37°C, cells were washed
twice with PBS and incubated in fresh
medium. Live cell images were acquired
by using a laser confocal scanning micro-
scope (Nikon), and the phagocytic index
was determined by measuring the fluo-
rescence intensity per cell by using the
Volocity software (PerkinElmer).
Endothelial Monolayer Permeability
Cell permeability was measured by
using the xCELLigence Real Time Cell
Analysis DP instrument (Roche). This
R E S E A R C H  A R T I C L E
M O L  M E D  1 7 ( 9 - 1 0 ) 1 0 4 5 - 1 0 5 5 ,  S E P T E M B E R - O C T O B E R  2 0 1 1  |  M E D I N A  E T  A L .  |  1 0 4 7
assay is based on measuring electrical re-
sistance between gold electrodes, which is
impeded by the integrity of the cell mono-
layer. Briefly, RMECs were plated on an
E-16 plate at a density of 20,000/ well in
200 μL of DMEM. Once RMECs had
formed a confluent monolayer, and at the
time of greatest impedance, the experi-
ment was paused while 100 μL of medium
was removed and replaced with fresh
DMEM alone or DMEM containing IL-8
(200 ng/mL) or VEGF (200 ng/mL) so
that final concentrations are 100 ng/ mL.
Cell impedance was recorded for another
12 h, and data were exported and ana-
lyzed by using Microsoft Excel 2007
 (Microsoft, Redmond, WA, USA).
Murine Model of Retinal Ischemia
C57BL/6 mice were purchased from
Harlan Laboratories, UK. All experi-
ments were performed in conformity to
the Association for Research in Vision
and Ophthalmology statement for the
use of animals in ophthalmic and vision
research and UK Home Office regula-
tions. Ischemic retinopathy was induced
in C57BL/6 mice by using the previously
described oxygen-induced retinopathy
model (OIR) (29). Briefly, mouse pups at
postnatal day 7 (P7) and their nursing
dams were exposed to 75% oxygen (Pro-
Ox 110 Chamber Controller, Biospherix,
Redfield, NY, USA) for 5 d to induce reti-
nal vasodegeneration. At P12, mice were
transferred back to room air to create
overt central retinal ischemia and re-
ceived an intravitreal injection into the
right eye containing 1 μL of 1 × 105
MACs that had previously been labeled
with Qtracker® 655 (Invitrogen). As a
control, phenol red-free DMEM contain-
ing no growth factors or serum was in-
jected into the left eye of each pup.
A separate group of mice received a
daily intraperitoneal injection of CXC-
chemokine receptor 2 (CXCR2) inhibitor
SB225002 (Enzo Life Sciences, Exeter,
UK) at a dose of 5μg/g from P12 until
P15. Pups were then euthanized by using
sodium pentobarbital, and the whole
eyes were fixed in 4% parafor maldehyde.
Retinal flat mounts were stained with
isolectin B4 (Sigma) and streptavidin-
Alexa 488 (Invitrogen). In a separate set
of experiments, unlabeled MACs were
injected and detected by using human-
 specific antibody CD68 (AbD Serotec).
Stained retinas were visualized and im-
aged by using a Nikon confocal scanning
microscope. Area quantification was done
by using Image J software (National Insti-
tutes of Health, Washington, DC, USA).
Analysis was also performed to quantify
the number of retinal phagocytes by
using NIS elements software (Nikon). 
Three-dimensional (3D) image recon-
struction was performed by using
 Volocity software (PerkinElmer).
Statistical Analysis
All data are expressed ± SEM. Statisti-
cal significance of differences between
groups was determined by using one-
way ANOVA with the Student-Newman-
Keuls posttest, with GraphPad InStat
version 3.06 for Windows (Graphpad
Software, San Diego, CA, USA).
All supplementary materials are available
online at www.molmed.org.
RESULTS
MACs Induce Endothelial Tube
Formation In Vitro in a Paracrine
Manner
To investigate whether MACs have
proangiogenic properties, we used the
3D matrigel tube formation assay, in
which RMECs form tubelike structures
(Figure 1A). A coculture approach, with
prelabeled RMECs (green) and MACs
(red), allowed unambiguous cell identifi-
cation and accurate tubulogenesis quan-
tification (Figure 1B). MACs did not
 incorporate into the microvascular net-
work, and they remained remote as
single spherical cells (Figure 1C). How-
ever, quantification of RMEC tube length
(Figure 1D) and tube area (Figure 1E)
 indicated that MACs significantly in-
creased RMEC tubulogenesis by approxi-
mately two-fold (P < 0.001). The lack of
physical interaction between MACs and
RMECs suggested a paracrine effect,
which was tested by adding MAC-
 conditioned medium (MAC-CM) to the
RMEC tube-formation assay. MAC-CM
significantly enhanced RMEC tube for-
mation (P < 0.05) (Figure 1F), confirming
that MACs release proangiogenic factors
into the medium.
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Figure 1. MACs induce retinal microvascular network formation. (A) Green-labeled RMECs
formed tubes in Matrigel. (B) Red-labeled MACs promoted RMEC tube formation. Scale
bars: 500 μm. (C) Higher magnification of coculture showing red-labeled MACs did not in-
corporate into the vascular network. Scale bar: 200 μm. (D) Quantification of tube length.
(D) Quantification of tube area. (E) Addition of MAC-CM significantly increased RMEC
tube formation as measured by tube length when compared with nonconditioned media.
Data expressed as mean ± SEM. ***P < 0.001 versus control; *P < 0.05 versus control.
MACs Promote Vascular Repair in the
Ischemic Retina In Vivo
We next explored the potential of
MACs to regulate ischemia-induced an-
giogenesis in vivo. The OIR model was
chosen because it adequately and consis-
tently reproduces ischemia-related reti-
nopathy in mice and is an established
model for assessing angiogenic re-
sponses (30). Quantum-dot (Qdot)-
 labeled MACs were delivered into the
vitreous of each mouse at P12 at the time
point in OIR during which the retina ini-
tially experiences hypoxic stimuli (30).
After 72 h (P15), the retinal vasculature
was evaluated. Injected MACs pene-
trated the retinal neuropile but did not
integrate into the resident vascular net-
work (Figure 2A). The MACs remained
within the retina, but localized to the
nerve fiber layer underneath the inner
limiting membrane (Supplemental
Video 1). MACs retained their myeloid
features in the host retina, such as CD68
expression and amoeboid/spherical mor-
phology (Figure 2B). None of the injected
MACs adopted a ramified morphology,
suggesting they did not become retinal
microglia or dendritic cells. Interestingly,
MACs delivered into the retina added to
host phagocytes and increased the total
amount of retinal amoeboid phagocytes
by three-fold (Supplementary Figure 1).
Despite the fact that MACs did not di-
rectly contribute to vascular formation
by incorporation into the endothelium,
they significantly induced intraretinal
angiogenesis and reperfusion in the is-
chemic retina, reducing avascular areas
by 67% compared with vehicle-injected
retinas (P < 0.05) (Figures 2C, D). There
was no difference in preretinal neovascu-
lar vessels between groups.
MACs Represent Alternative M2
Macrophages
Previously, we have reported that
from the genotypic, proteomic and
immuno phenotypic perspectives, MACs
are monocytic in nature (11); however, it
is unknown whether these cells acquire
M1/M2 macrophage polarization states.
To determine the MAC relationship to
monocytes, transcriptomes from three
biological replicates of MACs were com-
pared with peripheral blood circulating
monocytes sorted by their expression of
CD14. Statistical assessment for genes
enriched at least two-fold (false discov-
ery rate of 0.01) showed 943 upregulated
and 881 downregulated transcripts (Sup-
plementary Figure 2). Upregulated genes
included mRNAs encoding complement
factors, matrix metalloproteinases
(MMPs), VEGFB, CD163, and the mono-
cyte to the macrophage differentiation
associated gene MMD. Among the
downregulated genes were S100A12, ad-
hesion molecules ICAM3 and selectin L,
interferon regulatory factor-1, and
lysozyme. Furthermore, interactome anal-
ysis, performed by using visANT,
demonstrated that upregulated MAC
gene networks were linked to angiogen-
esis, endocytosis and antiinflammatory
pathways. Downregulated gene net-
works were associated with inflamma-
tion, apoptosis and proteasomes (Sup-
plementary Figure 3).
Further investigation, focusing specifi-
cally on M1/M2 markers and proangio-
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Figure 2. MACs promote vascular repair in the ischaemic retina. (A) Injected MACs la-
beled with red Qdots did not incorporate into the resident vascular network labeled in
green with isolectin. Scale bars: 100 μm. (B) Injected human MACs retained a myeloid
phenotype as demonstrated by expression of human-specific CD68 and typical amoe-
boid morphology. Scale bars: 75 μm. (C) Representative flat mounted retinas injected with
vehicle (Control) or MACs, respectively. Isolectin staining in green identifies retinal vascula-
ture, and avascular regions are outlined in yellow. Insets show ischaemic areas in white.
(D) Quantification of avascular areas and ratio of avascular/total retinal area shows that
injection of MACs into the eye significantly induced vascular repair compared with injec-
tion of vehicle injected. *P < 0.05 versus control.
genic genes, demonstrated that MACs
highly expressed M2 macrophage mark-
ers such as macrophage scavenger receptor 1
(MSR1), mannose receptor, C type 1
(MRC1), IL-10, TGFB2 (transforming
growth factor, beta 2), and CD163 (Fig-
ure 3A). By contrast, expression of the
proinflammatory M1 macrophage mark-
ers TNF (tumor necrosis factor), IL-1β, IL-6,
IL-12, and COX2 (cyto chrome c oxidase
subunit II), was minimal. In addition,
proangiogenic genes VEGFB, CTGF (con-
nective tissue growth factor), PDGFB
(platelet-derived growth factor beta polypep-
tide), NRP1 (neuropilin 1) and MMP-9
were also highly expressed. Normalized
gene expression profiles comparing
monocytes to MACs strongly corrobo-
rated previous findings (Figure 3B) and
highlighted significant upregulation of
proangiogenic genes and M2 macro -
phage markers, whereas M1 markers
were downregulated. Furthermore, when
we compared MACs to monocytes, gene
microarray results were validated by the
demonstration by real-time quantitative
reverse-transcription PCR of significant
upregulation of CD163, IL-10, MSR1,
chemokine (C-C motif) ligand 2 (CCL2),
MMP-9, and VEGFB, and downregula-
tion of IL-1β and PTGS2 (prostaglandin-
endoperoxide synthase 2) (Supplemen-
tary Figure 4).
To support transcriptomic data at the
protein level, fluorescence-activated cell
sorting (FACS) immunophenotyping was
performed (Supplementary Figure 5).
Corresponding with other analysis in the
current investigation, MACs shared
many characteristics with myeloid cells
because they express CD45, CD14 and
CD68. Expression of CD163 and CD206
suggested that MACs exhibit an M2
macrophage phenotype. Moreover,
MACs are not dendritic cells, because
they lack CD83 and CD209 expression.
Similar FACS immunophenotyping was
performed on colony-forming unit–
 endothelial cells (CFU-EC) CFU-Hill, a
third subtype of EPCs grown in vitro. As
expected, CFU-Hill represents a more
heterogeneous population of cells; how-
ever, the main population (82% of cells)
also express M2 markers CD163 and
CD206 (Supplementary Figure 6), sug-
gesting CFU-Hill and MACs are both M2
macrophages.
Alternative activated macrophages are
frequently described as professional
phagocytes involved in clearance of cel-
lular debris and apoptotic bodies during
tissue remodeling; therefore MACs
phagocytic activity was evaluated by
using fluorescent E. coli bioparticles. The
phagocytic index of MACs was equiva-
lent to M1 macrophages; however, their
cellular morphology was clearly different
(Supplementary Figure 7). Whereas
MACs had a spindle, elongated shape,
M1 macrophages showed distinctively
flat, “fried-egg–like” morphology. These
two contrasting macrophage morpholo-
gies have been described previously (31)
and are related to M2 and M1 pheno-
types, respectively.
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Figure 3. Transcriptome analysis revealed
that MACs represent angiogenic M2-
 activated macrophages. (A) Heat maps
of typical M1, M2 markers and proangio-
genic genes demonstrated that the MAC
gene signature is highly enriched for M2
markers, whereas expression of M1
macrophage markers was weak/low.
Proangiogenic genes were also highly ex-
pressed. (B) Gene expression profiles of
MACs were normalized to monocytes.
Proangiogenic genes (green) and M2
markers (purple) were upregulated and
M1 markers (red) were downregulated
compared with housekeeping genes
(blue).
Figure 4. Angiogenic cytokines produced
by MACs. (A) A human angiogenesis pro-
teome profiler array was used to identify
soluble factors released by cells to the
medium. RMECs secrete minimal amounts
of ET-1, and medium from a MAC and
RMEC coculture system showed significant
expression of proangiogenic proteins such
as MMP-9, IL-8, and MCP-1. Three pairs of
positive controls are included in the top
corners and bottom left corner. A pair of
negative control spots in the bottom right
corner indicates very low background lev-
els. (B) IL-8 proteome array assessment of
conditioned media of RMECs, MACs and
RMECs + MACs. (C) Quantification of pro-
teome profiler shown in (B) by densitome-
try (O. D., optical density); N = 6. (D) ELISA
quantification of IL-8 in conditioned media
of RMECs, MACs and RMECs + MACs. N = 4.
Data in (C) and (D) expressed as mean ±
SEM. ***P < 0.001 versus RMECs; *P < 0.05
versus RMECs; ns, not significant.
MACs Secrete Angiogenic Factors
To identify some of the angiogenic cy-
tokines and growth factors secreted by
MACs, we characterized the media from
previous coculture experiments de-
scribed in Figure 1. For this characteriza-
tion we used a human proteome array
for profiling the expression of 55 angio-
genesis-related proteins. Conditioned
media from RMECs alone in the 3D Ma-
trigel assay contained minimal levels of
detectable cytokines, with only endothe-
lin-1 protein being observed (Figure 4A).
By contrast, eight different proteins were
highly expressed in MAC-RMEC cocul-
ture media (Figure 4A), and these in-
cluded established proangiogenic cy-
tokines and enzymes such as IL-8,
monocyte chemotactic protein 1 (MCP-1)
and MMP-9.
Because IL-8 was the most abundant
protein in the coculture system, its ex-
pression was further assessed when cells
were cultured separately. Interestingly,
IL-8 was found in the conditioned media
of MAC cultures but not RMECs (Fig-
ure 4B). Results of densitometry analysis
indicated that IL-8 protein expression in
the conditioned media of MACs was
comparable to that found in the cocul-
tures (Figure 4C), suggesting that IL-8
comes from MACs and not from RMECs.
To further corroborate this finding, we
performed absolute quantification of IL-8
in the different conditioned media by en-
zyme-linked immunosorbent assay
(ELISA) (Figure 4D). In agreement with
previous findings, IL-8 in RMEC-condi-
tioned media was minimal (1.7 pg/ mL)
compared with MAC-conditioned media
(154.4 pg/mL). The amount of IL-8 in co-
cultures (142.6 pg/mL) was similar to
MAC-conditioned media. Taken together,
proteome analysis and ELISA results in-
dicated that IL-8 is being secreted by
MACs and not RMECs.
IL-8 Is Essential for MAC Proangiogenic
Effects
Continuing on from the identification
of MAC-derived cytokines, we sepa-
rately added neutralizing antibodies
against VEGF or IL-8 to the coculture
system (Figures 5A, B) to evaluate
whether the MAC proangiogenic effect
was dependent on release of these two
soluble factors. Interestingly, addition of
anti–IL-8 antibody (Figure 5D), but not
anti-VEGF (Figure 5C), significantly de-
creased RMEC tube formation to base-
line levels (Figure 5E). Respective IgG
isotype controls did not have any effect.
These results indicated that the MAC-
mediated angiogenic response is highly
dependent on secreted IL-8 but not
VEGF. In addition, a neutralizing anti-
body against VEGFR2 inhibited RMEC
tube formation induced by MACs (Sup-
plementary Figure 8). This result sug-
gests that although the MAC proangio-
genic effect on RMECs is independent of
extracellular VEGF, it still depends on ac-
tivation of the VEGF signaling pathway
downstream of VEGFR2.
To assess the importance of MAC-
 mediated IL-8 signaling in vivo, the OIR
mouse model was treated with the
CXCR2 inhibitor SB225002 to block IL-8–
receptor signal transduction. In contrast
to non–drug-treated controls, SB225002-
treated animals did not benefit from
MAC intravitreal injections, as shown by
the extent of avascular areas that were
comparable to vehicle-injected control
retinas (Figure 6). Only the mouse group
that received MACs but no SB225005
showed a significant decrease in retinal
ischemia (P < 0.001). This finding sug-
gests that the proangiogenic paracrine ef-
fect of MACs in vivo can be significantly
diminished by blocking CXCR2 receptor-
 mediated cytokine signaling.
IL-8 Activates VEGFR2 Independently
of VEGF
In our in vitro experiments we deter-
mined that blocking the bioactivity of ex-
tracellular VEGF did not inhibit MAC
proangiogenic effects (Figure 5). This
finding was surprising because it is es-
tablished that activation of VEGFR2 sig-
naling is critical for angiogenesis (32,33).
These data suggested that IL-8 could
transactivate VEGFR2, independently of
extracellular VEGF, as has been previ-
ously reported (34). To evaluate if this
transactivation phenomenon is central to
IL-8 angiogenic function, we treated en-
dothelial cells with 100 ng/mL IL-8 for
15 min, and assessed consequent
VEGFR2 phosphorylation. IL-8 induced
significant VEGFR2 phosphorylation
(Figure 7A), which indicated that IL-8 is
capable of transactivating the VEGF sig-
naling pathway. To test functionality of
VEGFR2 signaling induced by IL-8, we
assessed endothelial barrier permeability
because the effects of VEGF on permeabil-
ity are primarily mediated by VEGFR2
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Figure 5. The MAC proangiogenic para -
crine effect is dependent on secreted IL-8,
but independent of extracellular VEGF.
Using a PKH kit, we prelabeled RMECs in
green and MACs in red before culturing
them in the 3D Matrigel Tubulogenesis
Assay. Representative images are shown
of RMECs alone forming tubes (A); cocul-
tures of RMECs and MACs (B); addition of
IL-8 neutralizing antibody to a coculture
system (C); and addition of neutralizing
VEGF antibody to cocultures (D). Scale
bars for A–D: 250 μm. (E) Quantification of
tube areas in response to treatments.
Anti–IL-8 significantly decreased RMEC
tube formation; however, neutralizing VEGF
had no significant effect on RMEC tubulo-
genesis. Data are expressed as mean ±
SEM. **P < 0.01 versus control; *P < 0.05
versus control; ns: not significant.
(35). Recombinant human IL-8 decreased
RMEC monolayer impedance to the
same level as VEGF (Supplementary Fig-
ure 9). This result provides indirect evi-
dence that IL-8 is capable of  inducing
VEGFR2 signaling and downstream en-
dothelial permeability.
ERK phosphorylation was also investi-
gated to further evaluate IL-8 effects on
endothelial cells downstream of both
IL-8 and VEGF signaling. IL-8 signifi-
cantly induced phosphorylation of ERKs
in RMECs (Figure 7B). Addition of
SB225002 completely abrogated ERK
phosphorylation induced by IL-8 and in-
dicated that binding to the cognate re-
ceptor CXCR2 is required for phosphory-
lation of ERKs.
DISCUSSION
EPCs represent a range of cell types of
which only some have been definitively
proven to differentiate into endothelium
and incorporate into blood vessels (9,36).
The OEC (also called ECFC) subtype is
now widely regarded as the “true EPC,”
although, surprisingly, these cells have
yet to be used in the clinical context. In-
stead, in most patient-based studies to
date, investigators have used cells sorted
from the mononuclear fraction of periph-
eral blood with a narrow-range of mark-
ers, such as CD34. Such isolates contain a
high proportion of circulating monocytic
cells that we now refer to as “MACs.”
These cells have also been referred to as
proangiogenic hematopoietic progenitors
(37). These marrow-derived cells, which
have often been credited with the capac-
ity of becoming endothelium (38), were
first described as CD34+ colony-forming
cells that acquired the expression of en-
dothelial markers CD31, VEGFR2 and
Tie2 (39). However, these “endothelial”
markers are not specific, because they
have also been found in monocytic cells
(40). Indeed, it has been reported that
platelet microparticle uptake by mono -
nuclear cells in culture may explain the
presence of the endothelial markers
CD31 and von Willebrand factor in
MACs (41). For these reasons, alternative
names other than “EPC” have been pro-
posed, such as MACs, proangiogenic
monocytes and vascular accessory cells
(9,10). Novel evidence provided in the
current investigation strongly supports
the assertion that MACs are myeloid
cells with no potential to differentiate
into endothelium.
One of the key findings of the present
study was the recognition of MACs as al-
ternatively activated M2 macrophages
that support angiogenesis in a paracrine
manner. While investigating molecular
mechanisms to explain the proangio-
genic effects of MACs, we identified
striking immunophenotypic similarities
between these cells and M2 macro -
phages. MACs express typical M2 mark-
ers such as the macrophage scavenger re-
ceptor MSR1 (CD204), hemoglobin
scavenger receptor (CD163), mannose re-
ceptor MRC1 (CD206) and cytokine
IL-10. This new evidence is important be-
cause M2 macrophages have been shown
to function by dampening inflammatory
responses, scavenging cellular debris,
promoting angiogenesis, and enhancing
tissue repair (27,42). Our data indicate
that MACs represent alternative M2
macrophages and, as such, promote re-
pair and limit tissue injury.
Our data demonstrate that MACs have
the ability to mediate angiogenesis in
vitro and in vivo. They achieve this with-
out ever incorporating into the lumen of
vessels, and they often remain com-
pletely remote from the vasculature.
Therefore, MACs must influence angio-
genic behavior in a paracrine manner
through the release of cytokines or
growth factors and creation of a concen-
tration gradient to which endothelial
cells respond. Although this paracrine
 effect has previously been described
(15,18), respective molecular mechanisms
have not been addressed in sufficient de-
tail. Our data provide the first evidence
directly linking IL-8 secretion by MACS
to downstream VEGFR2 transactivation
and consequently ERKs phosphorylation
in mature endothelial cells. Although not
investigated in the current study, there is
recent evidence that some circulating
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Figure 6. Vascular repair induced by MAC delivery was blocked by CXCR2 inhibitor
SB225002. Flat mounted retina microvasculature was stained green with isolectin, and
avascular areas (insets) are outlined in white. A representative retina per group is shown:
(A) ischemic retina at P12; (B) vehicle-injected retina at P15; (C) MAC-injected retina at
P15; (D) MAC-injected retina at P15 in mouse that received SB225005 intraperitoneal in-
jections; (E) vehicle-injected retina at P15 in mouse that received SB225005 intraperi-
toneal injections; (F) quantification of avascular areas shows that SB225005 significantly in-
hibited MAC proangiogenic effects. N = 7; ***P < 0.001; ns: not significant.
blood-derived progenitor cells may form
transient, nanotubelike intercellular con-
nections to other distinct cell types that
act as conduits for transfer of proteins
and other macromolecules and thereby
alter function (43). Whether this is a fea-
ture of MAC communication with resi-
dent endothelium is uncertain. Further-
more, endothelium-derived cytokines
can also influence MAC phenotype and
behavior. Hence endothelial cell–MAC
interactions are highly complex, and we
are currently investigating key aspects of
this cellular cross-talk. In the current
study, however, our data consistently
demonstrated the existence of at least
one key component of intercellular com-
munication: MACs secrete IL-8, which
induces phosphorylation of VEGFR2 in
mature endothelial cells.
In the context of ischemic injury, we
have now shown that intravitreal deliv-
ery of MACs into the ischemic eye can
effectively promote retinal vascular re-
pair and reperfusion. Although this effect
has never been shown before in the eye,
the findings are consistent with reports
of the use of “MAC-like” cells to enhance
neovascularization of other ischemic tis-
sues in models of myocardial infarction
(13) and hind limb ischemia (14). These
data, in addition to ours, indicate that
MACs have similar vasoreparative prop-
erties in at least three different vascular
beds. Taken together, this evidence sup-
ports some of the preclinical and patient-
based evidence that MACs have the po-
tential to induce therapeutic
angiogenesis. However, it should be
noted that we have used a relatively ho-
mogenous population of cells selected
according to immunophenotype and cell
morphology, cultured in vitro, and that
such potent proangiogenic properties are
not common to all monocytic cells. In-
deed, transplanting freshly isolated
CD14+ cells,  cultured dendritic cells, or
cultured macrophages (M1) in a murine
hind-limb ischemic model did not im-
prove neovascularization; only MAC
transplantation significantly increased is-
chemic tissue revascularization (14). In
agreement with the results of these other
published studies, our microarray tran-
scriptional profiling results corroborated
other evidence that MACs are distinct
from freshly isolated monocytes, and
suggest that ex vivo culture conditions
are partly responsible for the acquisition
of a proangiogenic and antiinflammatory
phenotype. The in vivo cell type that cor-
relates with MACs is the alternative M2
macrophage. The role of macrophages in
tissue repair has recently been high-
lighted by work in wound healing, in
which the switch from M1 to M2
macrophages is required for resolution of
inflammation and physiologic wound
healing (44).
Other investigators have shown that
MACs have the potential to release a
range of cytokines (16,18,20). This find-
ing is consistent with the results of our
analysis, in which we identified IL-8,
MCP-1 and MMP-9 as being released by
MACs in relatively high concentrations.
In addition, our results have revealed
that IL-8 plays a critical role, as demon-
strated by the ability to abrogate the
proangiogenic effects of MACs by block-
ade of IL-8, a response that is indepen-
dent of extracellular VEGF. We have also
demonstrated that IL-8 transactivates
VEGFR2 and induces proangiogenic sig-
naling cascades that control processes
such as endothelial proliferation, migra-
tion and tube formation. Although we
focused on IL-8/VEGFR2/ERK signaling
pathways, other mechanisms to explain
IL-8–induced angiogenesis are also possi-
ble. For example, nuclear factor κ B
(NFκB) transcription, activation of
SREBPs (sterol regulatory element-
 binding proteins) and RhoA, and stimu-
lation of IP3 (inositol-1,4,5-trisphosphate)
production through activation of phos-
pholipase C, may also be involved. De-
lineation of other mechanisms by which
IL-8 regulates angio genesis should be the
focus of future  research.
Despite in vitro evidence indicating
that MAC-secreted IL-8 is necessary and
sufficient to induce RMEC angiogenesis,
the significant beneficial effect of inject-
ing MACs into an ischemic retina is un-
likely to be caused by IL-8 release alone.
As stated previously, MACs, acting as al-
ternative activated M2 macrophages, can
modulate inflammatory and immune re-
sponses to ischemia by secreting a range
of soluble factors (including IL-8) that
will modify tissue cytokine profiles and
thereby reduce tissue damage. A similar
mechanism has been reported to explain
neuroprotective effects of bone- marrow–
derived progenitor cells injected into a
murine model of ischemic brain injury
(45). Paracrine effects play a significant
role in tissue repair by modulating an-
giogenesis. The “secretory” nonendothe-
lial phenotype of MACs contrasts with
the “structural” endothelial phenotype of
OECs; therefore the combined use of
both EPC cell types may be an option for
cellular therapies (46). Although consid-
erably more work on such combinations
is required, in a murine hind-limb ische-
mia model, it has been demonstrated
that a mixed transplantation of MACs
and OECs results in superior neovascu-
larization in vivo compared with trans-
plantation of either cell alone (18).
To dissect molecular mechanisms, we
focused on IL-8 because this cytokine is
classically known as a macrophage-
 derived mediator of angiogenesis (47).
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Figure 7. IL-8 transactivates VEGFR2 and
induces ERK phosphorylation in endothe-
lial cells. (A) HMEC-1 cells were treated
with 100 ng/mL IL-8 for 15 min, followed by
immunoblot analysis using a phospho-
VEGFR2 antibody. IL-8 increased VEGFR2
phosphorylation levels compared with
controls; 100 ng/mL VEGF treatment was
used as a positive control. (B) RMECs were
also treated with 100 ng/mL IL-8 for 15 min,
and immunoblot analysis for phospho-ERKs
was performed. IL-8 induced ERK phospho-
rylation in RMECs; this effect was com-
pletely abolished by the CXCR2 inhibitor
SB225002.
Pathological neovascular states in the eye
such as proliferative diabetic retinopathy
and Eales disease were found to be asso-
ciated with high IL-8 levels in the vitre-
ous of these patients (unpublished data).
In addition, it was reported that the an-
giogenic effects of IL-8 in microvascular
endothelial cells are mediated by CXCR2
(48), and that IL-8 transactivates VEGFR2
(34). In the study we report here, we
demonstrated that the provascular repair
effect of MACs in vivo was abrogated
when CXCR2 signaling was inhibited,
and this result was consistent with in
vitro findings showing that MACs secrete
IL-8, which induces phosphorylation of
VEGFR2 and ERKs. This finding pro-
vides a mechanistic explanation for the
proangiogenic effect of MACs, although
it should be appreciated that CXCR2 has
a complex ligand-binding pattern that in-
cludes growth-related oncogene (GRO)1,
GRO3, GCP2 (granulocyte chemotactic
protein-2) and MIP2 (macrophage in-
flammatory protein-2) (49). Therefore we
cannot exclude a possible role for other
CXCR2 ligands acting alongside IL-8 in
cytokine-mediated angiogenesis. Never-
theless, we provide evidence demon-
strating that IL-8 is capable of inducing
VEGFR2 and ERK phosphorylation, a
 response that is dependent on CXCR2
binding but is independent of VEGF.
This evidence is in agreement with re-
cent findings that indicate physical inter-
actions between VEGFR2 and the IL-8 re-
ceptors, and that Src kinases are involved
upstream of receptor complex formation
and VEGFR2 transactivation (34). There-
fore, the VEGF-signaling pathway can be
added to the many downstream targets
of IL-8–receptor binding (50).
In the current study we demonstrated
that MACs have the ability to enhance an-
giogenesis; however, the concept of these
cells as solely proangiogenic with positive
reparative potential may be an oversim-
plification and could be misleading.
Macrophages are known to retain consid-
erable plasticity (42) and can respond to
environmental signals by changing be-
tween their M1 and M2 phenotypes. Al-
though we have now shown MACs to be
M2-macrophage like, it is possible that
certain environmental conditions, such as
chronic hypoxia, extensive tissue necro-
sis/apoptosis, inflammation, and/or a di-
abetic milieu, could trigger a phenotypic
switch that is associated with pathology
rather than repair. As an example of this,
it has been previously reported that dia-
betic EPCs (in this case MAC-like cells)
did not efficiently repair ischemic vascu-
lar damage (51). Indeed, such cells con-
verted to an anti angiogenic phenotype in
obese diabetic mice (52). This finding sug-
gests that clinicians who employ any fu-
ture therapy based on delivering MACs
should carefully take into account both
the source of the cells and the environ-
ment into which they will be injected, be-
cause these features will determine the
M1/M2 phenotype and the potential for
reparative  angiogenesis.
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